Cargando…

Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies

BACKGROUND: The quantitative suspension array technology (qSAT) is a useful platform for malaria immune marker discovery. However, a major challenge for large sero-epidemiological and malaria vaccine studies is the comparability across laboratories, which requires the access to standardized control...

Descripción completa

Detalles Bibliográficos
Autores principales: Ubillos, Itziar, Jiménez, Alfons, Vidal, Marta, Bowyer, Paul W., Gaur, Deepak, Dutta, Sheetij, Gamain, Benoit, Coppel, Ross, Chauhan, Virander, Lanar, David, Chitnis, Chetan, Angov, Evelina, Beeson, James, Cavanagh, David, Campo, Joseph J., Aguilar, Ruth, Dobaño, Carlota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984756/
https://www.ncbi.nlm.nih.gov/pubmed/29859096
http://dx.doi.org/10.1186/s12936-018-2369-3
_version_ 1783328657386766336
author Ubillos, Itziar
Jiménez, Alfons
Vidal, Marta
Bowyer, Paul W.
Gaur, Deepak
Dutta, Sheetij
Gamain, Benoit
Coppel, Ross
Chauhan, Virander
Lanar, David
Chitnis, Chetan
Angov, Evelina
Beeson, James
Cavanagh, David
Campo, Joseph J.
Aguilar, Ruth
Dobaño, Carlota
author_facet Ubillos, Itziar
Jiménez, Alfons
Vidal, Marta
Bowyer, Paul W.
Gaur, Deepak
Dutta, Sheetij
Gamain, Benoit
Coppel, Ross
Chauhan, Virander
Lanar, David
Chitnis, Chetan
Angov, Evelina
Beeson, James
Cavanagh, David
Campo, Joseph J.
Aguilar, Ruth
Dobaño, Carlota
author_sort Ubillos, Itziar
collection PubMed
description BACKGROUND: The quantitative suspension array technology (qSAT) is a useful platform for malaria immune marker discovery. However, a major challenge for large sero-epidemiological and malaria vaccine studies is the comparability across laboratories, which requires the access to standardized control reagents for assay optimization, to monitor performance and improve reproducibility. Here, the Plasmodium falciparum antibody reactivities of the newly available WHO reference reagent for anti-malaria human plasma (10/198) and of additional customized positive controls were examined with seven in-house qSAT multiplex assays measuring IgG, IgG(1–4) subclasses, IgM and IgE against a panel of 40 antigens. The different positive controls were tested at different incubation times and temperatures (4 °C overnight, 37 °C 2 h, room temperature 1 h) to select the optimal conditions. RESULTS: Overall, the WHO reference reagent had low IgG2, IgG4, IgM and IgE, and also low anti-CSP antibody levels, thus this reagent was enriched with plasmas from RTS,S-vaccinated volunteers to be used as standard for CSP-based vaccine studies. For the IgM assay, another customized plasma pool prepared with samples from malaria primo-infected adults with adequate IgM levels proved to be more adequate as a positive control. The range and magnitude of IgG and IgG(1–4) responses were highest when the WHO reference reagent was incubated with antigen-coupled beads at 4 °C overnight. IgG levels measured in the negative control did not vary between incubations at 37 °C 2 h and 4 °C overnight, indicating no difference in unspecific binding. CONCLUSIONS: With this study, the immunogenicity profile of the WHO reference reagent, including seven immunoglobulin isotypes and subclasses, and more P. falciparum antigens, also those included in the leading RTS,S malaria vaccine, was better characterized. Overall, incubation of samples at 4 °C overnight rendered the best performance for antibody measurements against the antigens tested. Although the WHO reference reagent performed well to measure IgG to the majority of the common P. falciparum blood stage antigens tested, customized pools may need to be used as positive controls depending on the antigens (e.g. pre-erythrocytic proteins of low natural immunogenicity) and isotypes/subclasses (e.g. IgM) under study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12936-018-2369-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5984756
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59847562018-06-07 Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies Ubillos, Itziar Jiménez, Alfons Vidal, Marta Bowyer, Paul W. Gaur, Deepak Dutta, Sheetij Gamain, Benoit Coppel, Ross Chauhan, Virander Lanar, David Chitnis, Chetan Angov, Evelina Beeson, James Cavanagh, David Campo, Joseph J. Aguilar, Ruth Dobaño, Carlota Malar J Methodology BACKGROUND: The quantitative suspension array technology (qSAT) is a useful platform for malaria immune marker discovery. However, a major challenge for large sero-epidemiological and malaria vaccine studies is the comparability across laboratories, which requires the access to standardized control reagents for assay optimization, to monitor performance and improve reproducibility. Here, the Plasmodium falciparum antibody reactivities of the newly available WHO reference reagent for anti-malaria human plasma (10/198) and of additional customized positive controls were examined with seven in-house qSAT multiplex assays measuring IgG, IgG(1–4) subclasses, IgM and IgE against a panel of 40 antigens. The different positive controls were tested at different incubation times and temperatures (4 °C overnight, 37 °C 2 h, room temperature 1 h) to select the optimal conditions. RESULTS: Overall, the WHO reference reagent had low IgG2, IgG4, IgM and IgE, and also low anti-CSP antibody levels, thus this reagent was enriched with plasmas from RTS,S-vaccinated volunteers to be used as standard for CSP-based vaccine studies. For the IgM assay, another customized plasma pool prepared with samples from malaria primo-infected adults with adequate IgM levels proved to be more adequate as a positive control. The range and magnitude of IgG and IgG(1–4) responses were highest when the WHO reference reagent was incubated with antigen-coupled beads at 4 °C overnight. IgG levels measured in the negative control did not vary between incubations at 37 °C 2 h and 4 °C overnight, indicating no difference in unspecific binding. CONCLUSIONS: With this study, the immunogenicity profile of the WHO reference reagent, including seven immunoglobulin isotypes and subclasses, and more P. falciparum antigens, also those included in the leading RTS,S malaria vaccine, was better characterized. Overall, incubation of samples at 4 °C overnight rendered the best performance for antibody measurements against the antigens tested. Although the WHO reference reagent performed well to measure IgG to the majority of the common P. falciparum blood stage antigens tested, customized pools may need to be used as positive controls depending on the antigens (e.g. pre-erythrocytic proteins of low natural immunogenicity) and isotypes/subclasses (e.g. IgM) under study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12936-018-2369-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-01 /pmc/articles/PMC5984756/ /pubmed/29859096 http://dx.doi.org/10.1186/s12936-018-2369-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Methodology
Ubillos, Itziar
Jiménez, Alfons
Vidal, Marta
Bowyer, Paul W.
Gaur, Deepak
Dutta, Sheetij
Gamain, Benoit
Coppel, Ross
Chauhan, Virander
Lanar, David
Chitnis, Chetan
Angov, Evelina
Beeson, James
Cavanagh, David
Campo, Joseph J.
Aguilar, Ruth
Dobaño, Carlota
Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
title Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
title_full Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
title_fullStr Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
title_full_unstemmed Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
title_short Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1–4), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
title_sort optimization of incubation conditions of plasmodium falciparum antibody multiplex assays to measure igg, igg(1–4), igm and ige using standard and customized reference pools for sero-epidemiological and vaccine studies
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984756/
https://www.ncbi.nlm.nih.gov/pubmed/29859096
http://dx.doi.org/10.1186/s12936-018-2369-3
work_keys_str_mv AT ubillositziar optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT jimenezalfons optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT vidalmarta optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT bowyerpaulw optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT gaurdeepak optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT duttasheetij optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT gamainbenoit optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT coppelross optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT chauhanvirander optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT lanardavid optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT chitnischetan optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT angovevelina optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT beesonjames optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT cavanaghdavid optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT campojosephj optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT aguilarruth optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies
AT dobanocarlota optimizationofincubationconditionsofplasmodiumfalciparumantibodymultiplexassaystomeasureiggigg14igmandigeusingstandardandcustomizedreferencepoolsforseroepidemiologicalandvaccinestudies